Orion Corporation: Managers’ transactions – Virve Laitinen

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2021 at 9.00 EET             

         

Orion Corporation: Managers’ transactions – Virve Laitinen

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

____________________________________________

Person subject to the notification requirement

Name: Laitinen, Virve

Position: Other senior manager

Issuer: Orion Oyj

LEI: 74370029VAHCXDR7B745

Notification type: INITIAL NOTIFICATION

Reference number: 74370029VAHCXDR7B745_20210226105402_2

____________________________________________

Transaction date: 2021-03-01

Venue not applicable

Instrument type: SHARE

ISIN: FI0009014377

Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION

Transaction details

(1): Volume: 5,243 Unit price: 0.00000 EUR

Aggregated transactions

(1): Volume: 5,243 Volume weighted average price: 0.00000 EUR

Orion Corporation

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.